We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$998M
AUM Growth
+$20.9M
Cap. Flow
-$63M
Cap. Flow %
-6.31%
Top 10 Hldgs %
28.11%
Holding
91
New
2
Increased
24
Reduced
43
Closed
3

Top Buys

Rank Stock Value
1
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$22M
2
CI icon
Cigna
CI
+$8.21M
3
AERI
Aerie Pharmaceuticals
AERI
+$7.07M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$6.46M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$6.29M

Top Sells

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$22.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$17.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
4
WBA
Walgreens Boots Alliance
WBA
+$12.6M
5
LOXO
Loxo Oncology, Inc
LOXO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Financials 1.12%
3 Technology 0.14%
4 Energy 0.14%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
51
DELISTED
Loxo Oncology, Inc
LOXO
$8.54M 0.86%
50,000
-72,961
-59% -$12.3M
XNCR icon
52
Xencor
XNCR
$1.55B
$8.18M 0.82%
209,854
-6,589
-3% -$269K
ONCE
53
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$7.51M 0.75%
137,691
-39,909
-22% -$2.73M
MGNX icon
54
MacroGenics
MGNX
$257M
$7.32M 0.73%
341,586
+16,586
+5% +$354K
OMCL icon
55
Omnicell
OMCL
$1.68B
$7.22M 0.72%
100,375
-10,000
-9% -$630K
REGN icon
56
Regeneron Pharmaceuticals
REGN
$80.8B
$6.87M 0.69%
17,000
– –
RIGL icon
57
Rigel Pharmaceuticals
RIGL
$750M
$6.79M 0.68%
211,399
+41,071
+24% +$1.23M
PTLA
58
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.45M 0.65%
242,302
-110,000
-31% -$3.59M
MD icon
59
Pediatrix Medical
MD
$2.2B
$5.82M 0.58%
+124,674
New +$5.72M
CNC icon
60
Centene
CNC
$32.5B
$5.79M 0.58%
80,000
-50,000
-38% -$3.47M
ADMS
61
DELISTED
Adamas Pharmaceuticals
ADMS
$5.48M 0.55%
273,593
-54,600
-17% -$1.28M
CHRS icon
62
Coherus Oncology
CHRS
$196M
$5.46M 0.55%
331,131
-18,869
-5% -$334K
RVNC
63
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.05M 0.51%
203,181
– –
VRAY
64
DELISTED
ViewRay, Inc.
VRAY
$4.84M 0.48%
516,623
– –
MDCO
65
DELISTED
Medicines Co
MDCO
$4.04M 0.4%
135,000
+25,000
+23% +$942K
ZGNX
66
DELISTED
Zogenix, Inc.
ZGNX
$2.98M 0.3%
60,000
+10,000
+20% +$509K
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$2.27M 0.23%
617,800
– –
PVLA
68
Palvella Therapeutics
PVLA
$2.27B
$1.68M 0.17%
3,750
– –
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$1.33M 0.13%
341,300
-700
-0.2% -$2.98K
PDCO
70
DELISTED
Patterson Companies, Inc.
PDCO
$941K 0.09%
+38,500
New +$912K
ADVM
71
DELISTED
Adverum Biotechnologies
ADVM
$931K 0.09%
15,397
– –
VIRX
72
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$855K 0.09%
12,218
– –
XOM icon
73
ExxonMobil
XOM
$634B
$520K 0.05%
6,111
-693
-10% -$56.7K
QCOM icon
74
Qualcomm
QCOM
$176B
$466K 0.05%
6,476
-771
-11% -$50.7K
CVX icon
75
Chevron
CVX
$366B
$456K 0.05%
3,733
– –
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rhenman & Partners Asset Management held 91 positions worth $998M, up 2.1% from $977M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $63M in Q3 2018, closing 3 positions and reducing 43 holdings. Its most notable exit was Express Scripts Holding Company, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pediatrix Medical worth $5.82M.

  • Rhenman & Partners Asset Management's largest Q3 2018 buy was Pediatrix Medical: 124,674 shares worth $5.82M.
  • Rhenman & Partners Asset Management added most to DIPLOMAT PHARMACY, INC. in Q3 2018, an estimated $22M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2018 reduction was Nektar Therapeutics, cutting an estimated $17.8M.
  • Rhenman & Partners Asset Management fully exited Express Scripts Holding Company in Q3 2018, selling an estimated $22.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $998M portfolio in Q3 2018.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 3 in Q3 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 2.1% quarter-over-quarter to $998M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2018, filed 3 Oct 2018.